Prostate Cancer

"As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.

“There are a lot of variables and factors in deciding what might be the entire first-line of therapy," says Adam B. Weiner, MD.

The approval of darolutamide in mCSPC was supported by data from the phase 3 ARANOTE trial.

In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.

Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo

“This was a positive study, resulting in a statistically significant improvement in the primary end point of rPFS in the intent-to-treat population," said Rana R. McKay, MD, FASCO.

The approval is supported by data from the pivotal phase 3 ARANOTE trial.

Clinical benefit rate was observed 5 (27%) patients in cohort 1, 7 (27%) patients in cohort 2, and 2 (11%) patients in cohort 3.

Explore the potential of ultra-low PSA testing in managing metastatic hormone-sensitive prostate cancer, balancing accessibility and cost considerations.

Explore the latest advancements in clinical trials for metastatic hormone-sensitive prostate cancer, focusing on innovative treatments and testing methods.

“As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.

Data also showed a positive trend in overall survival.

“Prior taxanes did not increase reported hematological adverse events during treatment with Ra-223,” the investigators reported.

A recap of the FDA submissions and regulatory decisions in urology from May 2025.

The addition of Ra223 to enzalutamide was associated with a 31% reduction in the risk of progression or death compared with enzalutamide alone.

The trial plans to enroll approximately 70 patients with mCRPC.

Campbell emphasized that although gender representation in medicine is shifting, structural and cultural biases continue to influence academic recognition.

Overall, 59% of patients achieved at least a 50% decline in PSA level.

The company plans to submit a Biologics License Application to the FDA at the end of 2026.

The test demonstrated comparable or superior performance in Black and Non-White men.

Jim C. Hu, MD, MPH, shares in-depth findings comparing urinary continence recovery across 3 RARP approaches.

However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.

Exploring the impact of ultra-sensitive PSA testing on treatment decisions for metastatic hormone-sensitive prostate cancer, enhancing patient outcomes and care efficiency.

In this video, part 4 of a 4-part series, panelists discuss how primary care providers can address patient questions on prostate cancer screening.

In this video, part 3 of a 4-part series, panelists discuss treatment planning for prostate cancer, particularly in older patients.

In this video, part 2 of a 4-part series, panelists discuss the increasing prevalence of de novo metastatic hormone-sensitive prostate cancer.

In this video, part 1 of a 4-part series, panelists discuss the nuances and challenges of prostate cancer screening.

A prostate cancer expert breaks down likelihood of a diagnosis of metastatic prostate cancer and touches on available treatment options.

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.